Prevention of End-Stage Renal Disease Due to Type 2 Diabetes

Hans-Henrik Parving, Hendrik Lehnert, Jens Bröchner-Mortensen, Ramon Gomis, Steen Andersen, Peter Arner, The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. The New England Journal of Medicine. ,vol. 345, pp. 870- 878 ,(2001) , 10.1056/NEJMOA011489

Yves Lacourcière, André Bélanger, Chantal Godin, Jean-Pierre Hallé, Stuart Ross, Noël Wright, Jean Marion, Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney International. ,vol. 58, pp. 762- 769 ,(2000) , 10.1046/J.1523-1755.2000.00224.X

William M. McClellan, Dawn F. Knight, Herbert Karp, Wendy W. Brown, Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: Important differences between practice and published guidelines American Journal of Kidney Diseases. ,vol. 29, pp. 368- 375 ,(1997) , 10.1016/S0272-6386(97)90197-9

Edmund J. Lewis, Lawrence G. Hunsicker, William R. Clarke, Tomas Berl, Marc A. Pohl, Julia B. Lewis, Eberhard Ritz, Robert C. Atkins, Richard Rohde, Itamar Raz, Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes The New England Journal of Medicine. ,vol. 345, pp. 851- 860 ,(2001) , 10.1056/NEJMOA011303

for the RENAAL Study Investigators* Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Parving HH, Remuzzi G, Snapinn S, Zhang X, Shahinfar S, None, EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY The New England Journal of Medicine. ,vol. 345, pp. 861- 869 ,(2001) , 10.1056/NEJMOA011161

Mordchai Ravid, David Brosh, Zohar Levi, Yosefa Bar-Dayan, Dorit Ravid, Rita Rachmani, Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Annals of Internal Medicine. ,vol. 128, pp. 982- 988 ,(1998) , 10.7326/0003-4819-128-12_PART_1-199806150-00004

C. E. Mogensen, S. Neldam, I. Tikkanen, S. Oren, R. Viskoper, R. W Watts, M. E Cooper, Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study BMJ. ,vol. 321, pp. 1440- 1444 ,(2000) , 10.1136/BMJ.321.7274.1440

Lubor Golan, John D. Birkmeyer, H. Gilbert Welch, The Cost-Effectiveness of Treating All Patients with Type 2 Diabetes with Angiotensin-Converting Enzyme Inhibitors Annals of Internal Medicine. ,vol. 131, pp. 660- 667 ,(1999) , 10.7326/0003-4819-131-9-199911020-00005

Lawrence Y Agodoa, Lawrence Appel, George L Bakris, Gerald Beck, Jacques Bourgoignie, Josephine P Briggs, Jeanne Charleston, DeAnna Cheek, William Cleveland, Janice G Douglas, Margaret Douglas, Donna Dowie, Marquetta Faulkner, Avril Gabriel, Jennifer Gassman, Tom Greene, Yvette Hall, Lee Hebert, Leena Hiremath, Kenneth Jamerson, Carolyn J Johnson, Joel Kopple, John Kusek, James Lash, Janice Lea, Julia B Lewis, Michael Lipkowitz, Shaul Massry, John Middleton, Edgar R Miller III, Keith Norris, Daniel O'Connor, Akinlou Ojo, Robert A Phillips, Velvie Pogue, Mahboob Rahman, Otelio S Randall, Stephen Rostand, Gerald Schulman, Winifred Smith, Denyse Thornley-Brown, C Craig Tisher, Robert D Toto, Jackson T Wright Jr, Shichen Xu, African American Study of Kidney Disease and Hypertension (AASK) Study Group, African American Study of Kidney Disease and Hypertension (AASK) Study Group, Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. ,vol. 285, pp. 2719- 2728 ,(2001) , 10.1001/JAMA.285.21.2719

N Chaturvedi, Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data Annals of Internal Medicine. ,vol. 134, pp. 370- 379 ,(2001)